Elekta has announced that Health Canada has issued a Medical Device License to Elekta’s Leksell Gamma Knife Icon radiosurgery system. Canadian health care providers are now able to offer their patients the latest advance in Elekta’s industry-leading stereotactic radiosurgery (SRS) system, the only SRS system designed specifically to target brain tissue, according to a company press release.
Icon is the sixth generation of the Leksell Gamma Knife system and provides the flexibility for single dose administration or multiple treatment sessions over time. This enables treatment of structures ranging from very small target sizes of a few millimeters to several centimeters, targets close to critical brain structures and new or recurring brain metastases.
“The image guidance and frameless features of Gamma Knife Icon allow us to treat patients who were not candidates for SRS therapy with older technologies,” said Arjun Sahgal, M.D., Deputy Chief of the Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto. “Through our experience participating in the pre-approval validation of this system, we had the opportunity to experience how real-time CT imaging enables sub-millimeter accuracy in targeting tumors. This degree of precision is especially critical when targeting lesions in the brain, where sparing healthy tissue is essential for reducing side effects and protecting normal brain function.”
Specific to Icon are the online Adaptive DoseControl and high-definition motion management technologies that ensure high accuracy for all treatments and an efficient workflow. Compared to other SRS platforms, Icon reduces delivery of radiation to normal brain tissue two to four times and lowers the extracranial dose by up to 130-fold. Icon can be used in both frameless and fractionated treatment approaches, expanding physician options for patient-specific needs.
Elekta’s Leksell Gamma Knife Icon radiosurgery system receives medical device license from Health Canada. Appl Rad Oncol.